L. rhamnosus bacterial lysate may improve HbA1c in type 2 diabetes
Key takeaway:
In a small randomized trial, three months of L. rhamnosus DV bacterial lysate improved HbA1c and waist circumference compared with placebo in adults with type 2 diabetes.
Study at a glance
What was studied
L. rhamnosus DV bacterial lysate added to standard care in type 2 diabetes.
Study type
Randomized Controlled Trials (RCTs)
duration
Short-Term (≤3 mo)
Intervention
Del-Immune V Extra bacterial lysate
Outcomes
HbA1c, Fasting glucose, Waist circumference, Insulin sensitivity, Beta-cell function, BMI, Body weight
Funding
Non-industry sponsored
Main effects
↓ HbA1c versus placebo after 3 months
↓ Waist circumference in exploratory between-group analysis
↑ Insulin sensitivity in exploratory analysis
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Del-Immune V Extra bacterial lysate (Supplements) |  Beta-cell function (Metabolic Health) | Increase | Limited |
Del-Immune V Extra bacterial lysate (Supplements) |  BMI (Weight & Anthropometrics) | Decrease | Limited |
Del-Immune V Extra bacterial lysate (Supplements) | Body weight (Weight & Anthropometrics) | Decrease | Limited |
Del-Immune V Extra bacterial lysate (Supplements) |  Fasting glucose (Glycemic Control) | Decrease | Limited |
Del-Immune V Extra bacterial lysate (Supplements) | HbA1c (Glycemic Control) | Decrease | Mixed |
Del-Immune V Extra bacterial lysate (Supplements) | Insulin sensitivity (Metabolic Health) | Increase | Mixed |
Del-Immune V Extra bacterial lysate (Supplements) | Waist circumference (Weight & Anthropometrics) | Decrease | Mixed |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Participants were randomly assigned to bacterial lysate or matching placebo in a double-blind parallel trial.
- The per-protocol analysis included 42 participants who completed the 3-month treatment and 3-month follow-up.
- No severe adverse events were reported, and gastrointestinal symptoms were similar between groups.
Who this applies to
Adults aged 18 to 70 with type 2 diabetes.
Keep in Mind
This was an add-on supplement trial, not a replacement for standard diabetes treatment.
Between the Lines
- Small sample size with 42 participants in the primary per-protocol analysis.
- No intention-to-treat analysis was reported in the excerpted results.
- Secondary outcomes were exploratory with nominal p-values only.
- One author was employed by the product manufacturer.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Journal Reference
Savytska M, Baka O, Manzhalii E, et al. Effect of probiotics derivatives (postbiotics and metabiotics) on glycemic control in individuals with type 2 diabetes: a randomized clinical trial (DELI_Diab study). Front Endocrinol (Lausanne). 2026;17:1802045. doi:10.3389/fendo.2026.1802045
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.